PETER E. WESTERWEEL (DORDRECHT)
DOUBLE TROUBLE
The clinical history of a 62-year-old patient diagnosed with chronic phase CML is discussed.
The patient is at increased risk for TKI toxicity, but also for disease progression. Indeed,
treatment is complicated by TKI related toxicity. Also, first one and later a second kinase
domain mutation occur. How to manage TKI therapy in this patient? Or should he be
considered a candidate for allogenic stem cell transplant?
